322 related articles for article (PubMed ID: 19675450)
1. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
Grin A; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
[TBL] [Abstract][Full Text] [Related]
2. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?
Masood S; Loya A; Khalbuss W
Diagn Cytopathol; 2003 Jun; 28(6):329-34. PubMed ID: 12768640
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
4. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
5. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.
Carder PJ; Garvican J; Haigh I; Liston JC
Histopathology; 2005 Mar; 46(3):320-7. PubMed ID: 15720418
[TBL] [Abstract][Full Text] [Related]
6. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
7. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63.
Douglas-Jones A; Shah V; Morgan J; Dallimore N; Rashid M
Histopathology; 2005 Aug; 47(2):202-8. PubMed ID: 16045782
[TBL] [Abstract][Full Text] [Related]
8. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
9. Utility of cytokeratin 5/6 and high-molecular-weight keratin in evaluation of cauterized surgical margins in excised specimens of breast ductal carcinoma in situ.
Nayak A; Bhuiya TA
Ann Diagn Pathol; 2011 Aug; 15(4):243-9. PubMed ID: 21420886
[TBL] [Abstract][Full Text] [Related]
10. The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best.
Reisenbichler ES; Adams AL; Hameed O
Am J Clin Pathol; 2013 Dec; 140(6):767-79. PubMed ID: 24225742
[TBL] [Abstract][Full Text] [Related]
11. The role of cytokeratin 5/6 as an adjunct diagnostic tool in breast core needle biopsies.
Nofech-Mozes S; Holloway C; Hanna W
Int J Surg Pathol; 2008 Oct; 16(4):399-406. PubMed ID: 18499686
[TBL] [Abstract][Full Text] [Related]
12. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
14. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Moriya T
J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
16. [Papillary lesions of the breast].
Ni YB; Tse GM
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):721-6. PubMed ID: 24447546
[No Abstract] [Full Text] [Related]
17. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
18. Significance of papillary lesions at percutaneous breast biopsy.
Valdes EK; Tartter PI; Genelus-Dominique E; Guilbaud DA; Rosenbaum-Smith S; Estabrook A
Ann Surg Oncol; 2006 Apr; 13(4):480-2. PubMed ID: 16474908
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S;
Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281
[TBL] [Abstract][Full Text] [Related]
20. Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised?
Kunju LP; Kleer CG
Hum Pathol; 2007 Jan; 38(1):35-41. PubMed ID: 17095049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]